Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
Inhibrx intends FDA submission after phase 2 bone cancer win
Ozekibart reduced the risk of disease progression or death by 52% compared to placebo and more than doubled median progression-free survival.
Darren Incorvaia
Oct 24, 2025 6:40am
ESMO: Exelixis' TKI reduces risk of death by 20%
Oct 20, 2025 2:30am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Olympus launches AI for spotting polyps in colonoscopy
Sep 30, 2025 11:30am
CytomX reports patient death from kidney injury in ADC trial
Aug 14, 2025 6:45am
Gilead hands back one Arcus cancer candidate from $725M deal
Aug 7, 2025 6:35am
